Nature

Does screening for inducible ischemia improve outcomes?

The DIAD trial investigators have demonstrated that screening for inducible myocardial ischemia did not improve overall clinical outcome in a contemporary cohort of patients with asymptomatic type 2 ...
Business Wire

Basking Biosciences Presents Positive Clinical Results from Safety and Dose-Escalation Study for First Reversible Thrombolytic Agent at ISC 2023

COLUMBUS, Ohio--(BUSINESS WIRE)--Basking Biosciences (Basking), a clinical-stage biopharmaceutical company developing the first reversible thrombolytic therapeutic for ischemic stroke, today presented ...
Business Wire

Basking Biosciences Doses First Patients in Phase 2 Clinical Trial of Reversible Thrombolytic BB-031 for Acute Ischemic Stroke

COLUMBUS, Ohio--(BUSINESS WIRE)--Basking Biosciences (Basking), a clinical-stage biopharmaceutical company developing a novel acute thrombolytic therapy, today announced that the first patients have ...
BioWorld

Fast-acting and reversible: Basking seeks to expand options in ischemic stroke

Acute thrombosis, including heart attack and stroke, is a leading cause of mortality worldwide. Yet only a small fraction of patients can be treated with current therapeutic or surgical interventions.
Medscape

The Intra-aortic Balloon Pump in High-risk Percutaneous Coronary Intervention

The rapid increase in the number of percutaneous coronary interventions being performed has led to a corresponding rise in the complexity of lesions attempted and the extent of patient comorbidities ...